Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyazit, Fatma, Beyazit, Yavuz, Tanoglu, Alpaslan, Haznedaroglu, Ibrahim C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392953/
https://www.ncbi.nlm.nih.gov/pubmed/32763660
http://dx.doi.org/10.1016/j.mehy.2020.110150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392953/
https://www.ncbi.nlm.nih.gov/pubmed/32763660
http://dx.doi.org/10.1016/j.mehy.2020.110150

Ejemplares similares